Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
Recent studies reveal immunotherapy failed to improve survival in small-cell lung cancer when combined with chemoradiation, while timing of immunotherapy after radiation therapy affects outcomes in non-small cell lung cancer patients.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
MajesTEC-9 trial demonstrates teclistamab's superiority over standard care in second-line multiple myeloma treatment, with significant progression-free survival and overall survival benefits supporting earlier use of the BCMA-targeting bispecific antibody.
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
Atara Biotherapeutics announced a Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel's Biologics License Application, held by partner Pierre Fabre Pharmaceuticals.
India's pharmaceutical industry, valued at Rs. 5.41 lakh crore in 2025, is transitioning from a generics powerhouse to an innovation-driven sector focused on biosimilars, complex formulations, and global R&D capabilities.
Study finds advanced melanoma patients with sufficient vitamin D levels showed better response rates and longer survival when receiving anti-PD-1 immunotherapy compared to those with low vitamin D status.
Cidara Therapeutics is approaching a critical interim analysis of its Phase 3 ANCHOR trial for CD388, an influenza prophylactic candidate. The results will determine whether the company proceeds with its planned Biologics License Application.
The bipolar depression treatment pipeline includes over 10 therapies from 8+ companies, with recent Phase 3 trials initiated for azetukalner and multiple emerging drugs targeting novel pathways expected to launch by 2036.
Researchers discovered that adding three common amino acids to lipid nanoparticles dramatically improves mRNA and CRISPR gene editing delivery, boosting efficiency up to 20-fold and raising gene editing success rates from 25% to nearly 90%.
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
New AI platforms are emerging to address rare disease diagnosis and epidemiology, as global costs reach up to $8.6 trillion annually affecting 300 million patients worldwide across more than 7,000 distinct conditions.
